Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protonix Average Price Increases By 8% As Wyeth Cuts Medicaid Contracts

This article was originally published in The Pink Sheet Daily

Executive Summary

Focus on key managed care accounts and elimination of some state contracts has resulted in an 8% weighted average price increase compared to first quarter 2004. Protonix shows 10% total prescription growth, but posts flat sales due to 9% inventory workdown.

You may also be interested in...

Wyeth More Optimistic On Medicare Rx As Plan Details Emerge

Medicare Rx plans will mimic managed care contracting system rather than Medicaid's preferred drug list structure, North American President Mahady predicts. Wyeth ends some Medicaid contracts for Protonix after states ask for deeper discounts on proton pump inhibitor.

Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth

Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.

Wyeth Pinning Near-Term Growth Hopes On Enbrel, Prevnar

The rheumatoid arthritis agent and pneumococcal conjugate vaccine are less sensitive to pricing pressure, giving them better growth prospects, the company says. Wyeth expects to file six "major" NDAs in next two years as it looks to new products to off-set pricing pressure over the long term.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts